Victory Capital Management
MLTX icon

Victory Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Victory Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,790
Closed -$135K – 2483
2025
Q3 		$135K Sell
18,790
-119,578
-86% -$6.23M ﹤0.01% 2263
2025
Q2 		$6.53M Sell
138,368
-119,782
-46% -$4.88M ﹤0.01% 1231
2025
Q1 		$10.1M Buy
258,150
+79,649
+45% +$3.43M 0.01% 1039
2024
Q4 		$9.67M Sell
178,501
-39,338
-18% -$2.01M 0.01% 1094
2024
Q3 		$11M Buy
217,839
+43,157
+25% +$2.02M 0.01% 1078
2024
Q2 		$7.68M Buy
174,682
+24,037
+16% +$1.02M 0.01% 1158
2024
Q1 		$7.57M Sell
150,645
-3,962
-3% -$215K 0.01% 1138
2023
Q4 		$9.34M Sell
154,607
-28,370
-16% -$1.46M 0.01% 1079
2023
Q3 		$10.4M Buy
182,977
+162,027
+773% +$8.94M 0.01% 998
2023
Q2 		$1.07M Buy
+20,950
New +$564K ﹤0.01% 1640

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Victory Capital Management's MLTX Position: Q4 2025 in Review

Victory Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 18,790 shares — an estimated $135K sold.

Victory Capital Management first reported a position in MLTX in Q2 2023 and held it in 10 quarters. The position peaked at $11M in Q3 2024. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

  • Victory Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Victory Capital Management sold 18,790 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $135K.
  • Victory Capital Management first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 10 quarters.
  • Victory Capital Management's MoonLake Immunotherapeutics position peaked at $11M in Q3 2024.
  • 130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Victory Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.